Galectin completes NAVIGATE randomization with 357 patients; topline results Q4 2024

GALECTIN THERAPEUTICS INC

Randomized 357 patients, exceeding initial target of ~315, in Phase 2b/3 belapectin study for NASH cirrhosis.
Last patient randomized end of February 2023; enrollment of new patients ended in late December 2022.
Study is first to evaluate primary prevention of esophageal varices in NASH cirrhosis with portal hypertension.
Topline interim results from Phase 2b portion expected in Q4 2024.
Trial enrolled patients across 14 countries on five continents.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.